share_log

Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Calais Philippe

Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Calais Philippe

Transcode Therapeutics | 4:持股变动声明-董事 Calais Philippe
美股SEC公告 ·  06/18 16:20

Moomoo AI 已提取核心信息

Philippe Calais, associated with Transcode Therapeutics, Inc. [RNAZ], has been involved in a transaction dated 06/14/2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, have not been disclosed. The relationship of Philippe Calais to the issuer has not been specified in the announcement. As such, the impact of this transaction on Calais's holdings in Transcode Therapeutics remains unclear.
Philippe Calais, associated with Transcode Therapeutics, Inc. [RNAZ], has been involved in a transaction dated 06/14/2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, have not been disclosed. The relationship of Philippe Calais to the issuer has not been specified in the announcement. As such, the impact of this transaction on Calais's holdings in Transcode Therapeutics remains unclear.
与Transcode Therapeutics, Inc. [RNAZ]相关的Philippe Calais涉及了一项日期为06/14/2024的交易。具体交易细节,包括股份数量、股份性质、交易价格以及股份总价值,尚未披露。Philippe Calais与发行人的关系在公告中未做说明。因此,这一交易对Calais在Transcode Therapeutics中的持股影响仍不明确。
与Transcode Therapeutics, Inc. [RNAZ]相关的Philippe Calais涉及了一项日期为06/14/2024的交易。具体交易细节,包括股份数量、股份性质、交易价格以及股份总价值,尚未披露。Philippe Calais与发行人的关系在公告中未做说明。因此,这一交易对Calais在Transcode Therapeutics中的持股影响仍不明确。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息